- Home
- ALGS vs MDAI Comparison
ALGS vs MDAI Comparison
Compare ALGS & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- MDAI
- Stock Information
- Founded
- ALGS 2018
- MDAI 2013
- Country
- ALGS United States
- MDAI United States
- Employees
- ALGS N/A
- MDAI N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- MDAI Medical/Dental Instruments
- Sector
- ALGS Health Care
- MDAI Health Care
- Exchange
- ALGS Nasdaq
- MDAI Nasdaq
- Market Cap
- ALGS 36.0M
- MDAI 37.8M
- IPO Year
- ALGS 2020
- MDAI N/A
- Fundamental
- Price
- ALGS $7.20
- MDAI $2.00
- Analyst Decision
- ALGS Strong Buy
- MDAI Strong Buy
- Analyst Count
- ALGS 1
- MDAI 2
- Target Price
- ALGS $70.00
- MDAI $4.75
- AVG Volume (30 Days)
- ALGS 156.2K
- MDAI 329.0K
- Earning Date
- ALGS 08-05-2025
- MDAI 05-13-2025
- Dividend Yield
- ALGS N/A
- MDAI N/A
- EPS Growth
- ALGS N/A
- MDAI N/A
- EPS
- ALGS N/A
- MDAI N/A
- Revenue
- ALGS $3,270,000.00
- MDAI $29,962,000.00
- Revenue This Year
- ALGS N/A
- MDAI N/A
- Revenue Next Year
- ALGS N/A
- MDAI $86.26
- P/E Ratio
- ALGS N/A
- MDAI N/A
- Revenue Growth
- ALGS N/A
- MDAI 55.21
- 52 Week Low
- ALGS $3.76
- MDAI $0.82
- 52 Week High
- ALGS $46.80
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- ALGS 62.71
- MDAI 77.95
- Support Level
- ALGS $5.47
- MDAI $1.57
- Resistance Level
- ALGS $6.12
- MDAI $1.73
- Average True Range (ATR)
- ALGS 0.59
- MDAI 0.11
- MACD
- ALGS 0.21
- MDAI 0.05
- Stochastic Oscillator
- ALGS 88.92
- MDAI 92.52
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.